Core Viewpoint - Heng Rui Medicine has shown strong performance in the stock market, with significant price increases and new clinical trial approvals for innovative drugs [1] Group 1: Stock Performance - Heng Rui Medicine (600276.SH) saw a peak increase of 6.61% to 73.42 CNY, marking a new high since June 16, 2021, with a year-to-date increase of approximately 60% [1] - Heng Rui Medicine (1276.HK) rose by 8.14% to 87.05 HKD, approaching a historical closing high, with a trading volume of 1 billion HKD and a market capitalization of 577.8 billion HKD [1] - Since its listing on the Hong Kong Stock Exchange on May 23, the stock price has increased by 97.62% from the issue price of 44.05 HKD [1] Group 2: Drug Approvals - The company announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of SHR-A2009, an antibody-drug conjugate targeting HER3, which has no similar drugs approved globally [1] - Additionally, the company received approval for clinical trials of HRS-7172 tablets, a new type of small molecule inhibitor for cancer treatment, with no similar drugs approved domestically or internationally [1]

消息面上，9月2日，恒瑞医药发布公告，近日，该公司收到国家药品监督管理局(以下简称"国家药监 局")核准签发关于HRS-7172片的《药物临床试验批准通知书》，将于近期开展临床试验。 HRS-7172片是公司自主研发的新型抗肿瘤小分子抑制剂。经查询，目前国内外尚无同类药物获批上 市。截至目前，HRS-7172片相关项目累计研发投入约2,841万元。 恒瑞医药（600276）(01276)再涨超5%，截至发稿，涨5.47%，报84.9港元，成交额1.53亿港元。 ...

Core Viewpoint - Heng Rui Medicine (01276) has seen a stock price increase of over 5%, currently trading at 84.9 HKD with a transaction volume of 153 million HKD, following the announcement of clinical trial approval for its new anti-tumor drug HRS-7172 [1] Group 1 - The company received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-7172 tablets [1] - HRS-7172 is a new small molecule inhibitor for anti-tumor treatment, developed independently by the company [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2 - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million CNY [1]

格隆汇9月2日丨恒瑞医药(01276.HK)公告，近日，公司收到国家药品监督管理局（以下简称"国家药监 局"）核准签发关于HRS-7172片的《药物临床试验批准通知书》，将于近期开展临床试验。 HRS-7172片是公司自主研发的新型抗肿瘤小分子抑制剂。经查询，目前国内外尚无同类药物获批上 市。截至目前，HRS-7172片相关项目累计研发投入约2,841万元。 ...

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor developed by the company [1] Group 1: Product Development - HRS-7172 tablets are a novel anti-tumor small molecule inhibitor independently developed by the company [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million yuan [1]